87 related articles for article (PubMed ID: 8040130)
1. In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study.
Marco F; Jones RN; Hoban DJ; Pignatari AC; Yamane N; Frei R
J Antimicrob Chemother; 1994 Mar; 33(3):647-54. PubMed ID: 8040130
[No Abstract] [Full Text] [Related]
2. In vitro comparison activity of OPC-17116, a new fluoroquinolone, against more than 5,000 recent clinical isolates from five medical centers.
Sader HS; Jones RN; Allen SD; Gerlach EH; Murray PR; Washington JA
J Chemother; 1993 Oct; 5(5):283-8. PubMed ID: 8106899
[TBL] [Abstract][Full Text] [Related]
3. NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients.
Mikamo H; Kawazoe K; Izumi K; Ito K; Tamaya T
Drugs; 1995; 49 Suppl 2():326-30. PubMed ID: 8549350
[No Abstract] [Full Text] [Related]
4. In-vitro activity of OPC-17116 against bacterial enteric pathogens.
Arduino RC; Frosolono M; Murray BE
J Antimicrob Chemother; 1994 Sep; 34(3):403-7. PubMed ID: 7829414
[No Abstract] [Full Text] [Related]
5. Postantibiotic effects of E-4868 and OPC-17116.
Sanford MD; Jones RN
J Antimicrob Chemother; 1993 Dec; 32(6):916-7. PubMed ID: 8144440
[No Abstract] [Full Text] [Related]
6. Plasma bactericidal activity of a new C-5 methyl fluoroquinolone after oral doses of 400 and 800 mg.
Gu JW; Fang W; Neu HC
J Clin Pharmacol; 1992 Sep; 32(9):804-7. PubMed ID: 1331205
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones.
Prats G; Roig C; Miró E; Navarro F; Mirelis B
Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):328-34. PubMed ID: 12072950
[No Abstract] [Full Text] [Related]
8. In-vitro antimicrobial activity of the new fluoroquinolone, grepafloxacin, against pathogenic Nocardia spp.
Yazawa K; Mikami Y
J Antimicrob Chemother; 1995 Apr; 35(4):541-4. PubMed ID: 7628988
[No Abstract] [Full Text] [Related]
9. Tentative interpretive criteria and quality control parameters for in-vitro susceptibility testing of Neisseria gonorrhoeae to two fluoroquinolones (PD 131628 and grepafloxacin (OPC 17116)).
Sewell DL; Barry AL; Allen SD; Fuchs PC; Murray PR; Tenover FC
J Antimicrob Chemother; 1996 Jan; 37(1):139-43. PubMed ID: 8647755
[TBL] [Abstract][Full Text] [Related]
10. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.
Wise R; Andrews JM; Brenwald N
J Antimicrob Chemother; 1993 Apr; 31(4):497-504. PubMed ID: 8390433
[TBL] [Abstract][Full Text] [Related]
11. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.
Montanari MP; Mingoia M; Varaldo PE
Antimicrob Agents Chemother; 2001 Dec; 45(12):3616-22. PubMed ID: 11709353
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity of BAY Y 3118 against selected species.
Verbist L; Verhaegen J
Drugs; 1995; 49 Suppl 2():264-5. PubMed ID: 8549326
[No Abstract] [Full Text] [Related]
13. Synthesis and in vitro antibacterial activity of N-[5-(5-nitro-2-furyl)-1,3,4-thiadiazole-2-yl] piperazinyl quinolone derivatives.
Foroumadi A; Ashraf-Askari R; Moshafi MH; Emami S; Zeynali A
Pharmazie; 2003 Jun; 58(6):432-3. PubMed ID: 12857013
[No Abstract] [Full Text] [Related]
14. In vitro activity of MF 5137, a new potent 6-aminoquinolone.
Wise R; Pagella PG; Cecchetti V; Fravolini A; Tabarrini O
Drugs; 1995; 49 Suppl 2():272-3. PubMed ID: 8549329
[No Abstract] [Full Text] [Related]
15. Comparative in vitro activity of BAY Y 3118 with other fluoroquinolones.
Molinari G; Schito GC
Drugs; 1995; 49 Suppl 2():222-5. PubMed ID: 8549310
[No Abstract] [Full Text] [Related]
16. In vitro activity of lomefloxacin, a new difluorinated quinolone, against urinary bacterial isolates: comparison with enoxacin and ofloxacin.
Azadian BS; Talboys CA; Roberts AP
J Chemother; 1989 Jul; 1(4 Suppl):176-7. PubMed ID: 16312357
[No Abstract] [Full Text] [Related]
17. The in-vitro activity of a new highly active quinolone, DU-6859a.
Jolley A; Andrews JM; Brenwald N; Wise R
J Antimicrob Chemother; 1993 Nov; 32(5):757-63. PubMed ID: 8125840
[No Abstract] [Full Text] [Related]
18. Antibacterial properties of AM-1155, a new 8-methoxy quinolone.
Hosaka M; Kinoshita S; Toyama A; Otsuki M; Nishino T
J Antimicrob Chemother; 1995 Aug; 36(2):293-301. PubMed ID: 8522459
[TBL] [Abstract][Full Text] [Related]
19. The antimicrobial activity of sparfloxacin, a new quinolone.
Paradelis AG; Delidou K; Grigoriadou A; Salpigides G; Pangalis A
Drugs; 1995; 49 Suppl 2():238-9. PubMed ID: 8549316
[No Abstract] [Full Text] [Related]
20. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Bauernfeind A
J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
